TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05363605

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: vofatamab
Description: Vofatamab is a Fibroblast Growth Factor Receptor 3 (FGFR3)-targeting human monoclonal antibody without a radioisotope. In Phase 1, the dose depends on cohort assignment. In Phase 2, if pre-dosing with vofatamab is indicated, the RP2D regimen will be administered.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: vofatamab
Description: Vofatamab is a Fibroblast Growth Factor Receptor 3 (FGFR3)-targeting human monoclonal antibody without a radioisotope. In Phase 1, the dose depends on cohort assignment. In Phase 2, if pre-dosing with vofatamab is indicated, the RP2D regimen will be administered.
Study: NCT05002530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aerosolized 13 cis retinoic acid plus Vitamin D
Description: Patients with Post COVID-19 Anosmia (Loss of Smell) will receive one dose daily of Aerosolized 13 cis retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 3 weeks. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aerosolized All trans retinoic acid plus Vitamin D
Description: Patients with Post COVID-19 Anosmia (Loss of Smell) will receive one dose daily of Aerosolized All trans retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 3 weeks. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
Study: NCT06515210

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants (n=23) incorporate the placebo into their usual diet daily.
Study: NCT06223555

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fixed Mixed Meal Test
Description: a FIXED dose meal that will be 900 kcal of a liquid meal

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adjusted Mixed Meal Test
Description: a body weight ADJUSTED dose liquid meal.~(30% of total daily energy requirements)
Study: NCT06459869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NG-350A IV administration
Description: a tumour-selective anti-CD40-expressing adenoviral vector

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine oral administration
Description: chemotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: long-course intensity-modulated radiotherapy
Study: NCT04602572

Intervention type: BEHAVIORAL
Intervention: Lifestyle course.
Description: Pharmacotherapy

Intervention type: PROCEDURE
Intervention: Bariatric surgery.
Description: Sleeve gastrectomy or gastric bypass.
Study: NCT06083480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GlyNAC (combination of glycine and n-acetylcysteine)
Description: GlyNAC 200 mg/kg/day (100mg glycine and 100mg N-acetyl-cysteine) will be administered orally in two divided doses each day for four weeks prior to TKA and six weeks postoperatively. The preparation will be a commercially available product of 1:1 ratio of glycine and N-acetyl-cysteine.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (alanine) 200 mg/kg/day will be administered orally in two divided doses each day for four weeks prior to TKA and six weeks postoperatively.
Study: NCT05359510

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: prophylactic mesh repair at different sites for prevention of incisional hernia after various abdominal incision versus primary abdominal suturing
Description: before closure of the abdominal layers prophylactic mesh will be used for prevention of incisional hernia. another patient with abdominal incision , primary closure of abdominal layer will occur.
Study: NCT05002530

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard therapy
Description: Standard therapy
Study: NCT04697212

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthcare team- + patient-directed intervention
Description: Participants will experience a clinical encounter with a healthcare team that has received training on evidence-based communication strategies for patients with communication disabilities, and will also complete a patient prompt list that elicits strategies that they prefer the healthcare team to use during their visit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthcare team-directed intervention
Description: Participants will experience a clinical encounter with a healthcare team that has received training on evidence-based communication strategies for patients with communication disabilities.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthcare team-directed intervention
Description: Participants will experience a clinical encounter with a healthcare team that has received training on evidence-based communication strategies for patients with communication disabilities.
Study: NCT05470075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR18042 tablets
Description: Drug: HR 18042 tablets 175mg and placebos match to Tramadol hydrochloride SR Tablets Dosing frequency: single dose; Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR18042 tablets
Description: Drug: HR 18042 tablets 225mg and placebos match to Tramadol hydrochloride SR Tablets Dosing frequency: single dose; Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR18042 tablets
Description: Drug: HR 18042 tablets 275mg and placebos match to Tramadol hydrochloride SR Tablets Dosing frequency: single dose; Route of administration: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol hydrochloride SR Tablets
Description: Drug: Tramadol hydrochloride SR Tablets 100mg and placebos match to HR18042 tablets Dosing frequency: single dose; Route of administration: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Drug: Placebos match to HR18042 tablets and Tramadol hydrochloride SR Tablets Dosing frequency: single dose; Route of administration: oral
Study: NCT01230762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapoxetine
Description: 60 mg tablet once daily as needed (prn) (with a possible dose reduction to 30 mg once daily) for up to 9 months
Study: NCT06646809

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alpha-ketoglutarate
Description: Alpha-ketoglutarate supplements

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets

Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Description: Standard care
Study: NCT06646445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200mg IV q3w day 1 of 21-day cycle
Description: Pembrolizumab 200 mg via a 30-minute IV infusion q3w on Day 1 of each 21-day cycle; 8 cycles ± 9 additional cycles (17 cycles in total).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Watch-and-wait approach
Description: Watch-and-wait strategy:~* TAP-CT scan every 3 months (± 7 days) for 2 years from inclusion.~* Colonoscopy with biopsies at months 3, 6, 12, 24.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Standard of care surgery performed with a maximal delay of 21 days (3 weeks) from inclusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant chemotherapy
Description: Adjuvant chemotherapy (5-fluorouracil/capecitabine ± oxaliplatin 3 months to 6 months) will be prescribed according to the current guidelines, at the investigator's discretion.
Study: NCT05492123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab 40 mg in 4 ml Injection
Description: Nivolumab 1mg/kg every 3 weeks for 4 cycles prior to radiation and 240mg every 2 weeks with concurrent radiation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab 200 MG in 40 ML Injection
Description: Ipilimumab 3mg/kg every 3 weeks for 4 cycles prior to radiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chemoradiation
Description: Radiation to a dose of 45Gy over 25 1.8Gyfractions and brachytherapy with concurrent weekly cisplatin 40mg/m2/w or carboplatin AUC 2/w

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Chemoradiation
Description: Radiation to a dose of 45Gy over 25 1.8Gyfractions and brachytherapy with concurrent weekly cisplatin 40mg/m2/w or carboplatin AUC 2/w
Study: NCT05436600

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: The exercise intervention group will undergo 12 weeks of AeroBal exercise training (approximately 3 times/week). Each exercise session will consist of a 5-minute warm-up walk, approximately 30 minutes of aerobic exercise at a goal of 60-75% HRmax, 15 minutes of balance exercises, and a 5-minute cool-down walk.
Study: NCT05503875

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab, secukinumab, ixekizumab, guselkumab, Jak inhibitors, methotrexate
Description: Psoriasis patients will be treated with adalimumab, secukinumab, ixekizumab, guselkumab, Jak inhibitors or methotrexate.
Study: NCT04866680

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Personalized Circulating DNA follow-up
Description: FFPE tissue sample will be collected before and after surgery blood samples will be collected before and after surgery and every 3 to 4 months
Study: NCT04600362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]
Description: Subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Experimental: Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]
Description: Subcutaneous
Study: NCT06314451

Intervention type: OTHER
Intervention: Cognitive Interview
Description: The study involves a single cognitive interview with a researcher, either online, by telephone, or face-to-face. People who want to take part will be given information about the study and asked to give written consent. Then they will be asked to talk about the wording of the questionnaire and how relevant it is to them.~Cognitive interviewing is recognized as a significant part of developing questionnaires for patient reported outcome measures (PROMs). The cognitive interviewing process used in PROM development will be adapted in this study to test the Steroid PRO in new disease populations. Cognitive interviewing will be carried out using pragmatic, light-touch interviews, underpinned by think aloud techniques and clean language principles.

Intervention type: OTHER
Intervention: Cognitive Interview
Description: The study involves a single cognitive interview with a researcher, either online, by telephone, or face-to-face. People who want to take part will be given information about the study and asked to give written consent. Then they will be asked to talk about the wording of the questionnaire and how relevant it is to them.~Cognitive interviewing is recognized as a significant part of developing questionnaires for patient reported outcome measures (PROMs). The cognitive interviewing process used in PROM development will be adapted in this study to test the Steroid PRO in new disease populations. Cognitive interviewing will be carried out using pragmatic, light-touch interviews, underpinned by think aloud techniques and clean language principles.
Study: NCT05414266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is acetone. At baseline, the investigator will record the area that will be treated in mm2 . Use of a 1 mm x 1 mm gridded transparency will be used to record the treatment area at baseline. At subsequent visits, the study intervention will be applied to the entire treatment area defined at baseline, regardless of any new hair growth. The assigned study intervention is applied monthly by the PI (or designee) to the treatment areas affected by AA on the scalp and/or eyebrows identified at Baseline. The topical solution is applied with a cotton tip applicator by the PI or their qualified designee. Solution is applied by gently pressing a cotton tip applicator that has been soaked in the study solution against the skin. Treatment is repeated monthly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SADBE 5%
Description: SADBE 5% is a solution of 5% Squaric Acid Dibutyl Ester (SADBE) in acetone. At baseline, the investigator will record the area that will be treated in mm2 . Use of a 1 mm x 1 mm gridded transparency will be used to record the treatment area at baseline. At subsequent visits, the study intervention will be applied to the entire treatment area defined at baseline, regardless of any new hair growth. The assigned study intervention is applied monthly by the PI (or designee) to the treatment areas affected by AA on the scalp and/or eyebrows identified at Baseline. The topical solution is applied with a cotton tip applicator by the PI or their qualified designee. Solution is applied by gently pressing a cotton tip applicator that has been soaked in the study solution against the skin. Treatment is repeated monthly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SADBE 5%
Description: SADBE 5% is a solution of 5% Squaric Acid Dibutyl Ester (SADBE) in acetone. At baseline, the investigator will record the area that will be treated in mm2 . Use of a 1 mm x 1 mm gridded transparency will be used to record the treatment area at baseline. At subsequent visits, the study intervention will be applied to the entire treatment area defined at baseline, regardless of any new hair growth. The assigned study intervention is applied monthly by the PI (or designee) to the treatment areas affected by AA on the scalp and/or eyebrows identified at Baseline. The topical solution is applied with a cotton tip applicator by the PI or their qualified designee. Solution is applied by gently pressing a cotton tip applicator that has been soaked in the study solution against the skin. Treatment is repeated monthly.
Study: NCT04703361

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo NaCl
Description: Placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo NaCl
Description: Placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Niacin
Description: B3 vitamin, Niacin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Na-3-OHB
Description: Na-3-OHB
Study: NCT05842005

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mesh-reduced Sling
Description: In this proposed study, the investigators aim to evaluate the role of using a ¾ x ⅜ inch cm polypropylene mesh suspended by sutures as a mesh-reduced solution for SUI.
Study: NCT05840328

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine Injection [Precedex]
Description: interventional drug will be administred either intravenously or epidurally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine Injection [Precedex]
Description: interventional drug will be administred either intravenously or epidurally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Injection
Description: intervention drug will be administred epidurally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Injection
Description: intervention drug will be administred epidurally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine Injection
Description: intervention drug will be administred epidurally
Study: NCT06412458

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IM83 CAR-T Cells
Description: IM83 CAR-T Cells, 5×10\^8 cells, 1×10\^9 cells, and 2×10\^9 cells, treatment follows a lymphodepletion. Drug: Fludarabine Recommendation: 30 mg/m\^2 (D-5\~D- 3), determined by tumor burden at baseline. Drug: Fludarabine Recommendation: 30 mg/m\^2 (D-5\~D-3), determined by tumor burden at baseline. Drug: Cyclophosphamide Recommendation: 300 mg/ m\^2 (D-5\~D-3), determined by tumor burden at baseline.
Study: NCT04853108

Intervention type: OTHER
Intervention: Remote Monitoring of COVID-19
Description: Remote monitoring of acute COVID-19 illness included use of a Medtronic pulse oximeter, photoplethysmography (PPG), patient-reported symptoms data, static vital signs captured during the course of the clinical evaluation and various physiomarkers.
Study: NCT06517550

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: positive end-expiratory pressure while mechanical ventilation
Description: a parameter in ventilator
Study: NCT04832750

Intervention type: DEVICE
Intervention: intermittent theta burst stimulation (iTBS) or sham stimulation
Description: 30 sessions of iTBS over 2 weeks (3 sessions per day, 5 days per week)

Intervention type: DEVICE
Intervention: intermittent theta burst stimulation (iTBS) or sham stimulation
Description: 30 sessions of iTBS over 2 weeks (3 sessions per day, 5 days per week)
Study: NCT05949541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg
Description: Everolimus is a kind of mTOR inhibitor which has been approved to use in several kinds of cancers, especially in metastatic breast cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDK4/6 Inhibitor SHR6390
Description: Dalpiciclib (SHR6390) is a kind of CDK4/6 inhibitor that has demonstrated tolerability and preliminary clinical activity in patients with heavily pretreated hormone receptor-positive, HER2-negative advanced breast cancer.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CDK4/6 Inhibitor SHR6390
Description: Dalpiciclib (SHR6390) is a kind of CDK4/6 inhibitor that has demonstrated tolerability and preliminary clinical activity in patients with heavily pretreated hormone receptor-positive, HER2-negative advanced breast cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitor and Fulvestrant combined with CDK4/6 inhibitors
Description: Endocrine therapy combined with CDK4/6 inhibitors is the standard first-line therapy for advanced luminal breast cancer. Investigators choose endocrine therapy including Letrozole, Anastrozole, Exemestane, and Fulvestrant. Postmenopausal participants should use Goserelin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aromatase inhibitor and Fulvestrant combined with CDK4/6 inhibitors
Description: Endocrine therapy combined with CDK4/6 inhibitors is the standard first-line therapy for advanced luminal breast cancer. Investigators choose endocrine therapy including Letrozole, Anastrozole, Exemestane, and Fulvestrant. Postmenopausal participants should use Goserelin.
Study: NCT05057117

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microwave thermolysis
Description: Baseline treatment with microwave thermolysis in one axilla and botulinum toxin A in the contralateral axilla, as allocated by randomization

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin A
Description: Baseline treatment with microwave thermolysis in one axilla and botulinum toxin A in the contralateral axilla, as allocated by randomization
Study: NCT06545630

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor antigen-sensitized DC vaccine
Description: subcutaneous administration
Study: NCT04989972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PSIL428
Description: 1 mg of psilocybin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oyster mushroom
Description: 1 mg of oyster mushroom
Study: NCT05639634

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chlorella supplementation
Description: Supplementation with Chlorella (1.5 g/d) in 3 capsules for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chlorella supplementation
Description: Supplementation with Chlorella (1.5 g/d) in 3 capsules for 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 12 week cardiovascular training programme
Description: Participants will be asked to complete a 12 week cycling training programme. This will consist of 4 X 50 min sessions per week. Each exercise session will include a warm-up phase (\~ 5 min), a main physical conditioning phase (\~ 40 min), and a cool-down phase (\~ 5 min).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 12 week cardiovascular training programme
Description: Participants will be asked to complete a 12 week cycling training programme. This will consist of 4 X 50 min sessions per week. Each exercise session will include a warm-up phase (\~ 5 min), a main physical conditioning phase (\~ 40 min), and a cool-down phase (\~ 5 min).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Supplementation
Description: Supplementation with Placebo - microcrystalline cellulose (1.5 g/d) in 3 capsules for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Supplementation
Description: Supplementation with Placebo - microcrystalline cellulose (1.5 g/d) in 3 capsules for 12 weeks.
Study: NCT05654779

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LCAR-AMDR Cells Product
Description: Subjects will receive a conditioning regimen before treatment with LCAR-AMDR cells
Study: NCT06496087

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DEPREXIL
Description: The trial group will be administered 1 capsule of DEPREXIL orally every 8 hours for 6 months of treatment.
Study: NCT04989972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PSIL428
Description: 1 mg psilocybin
Study: NCT04984759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine
Description: Primaquine GPO® (Government Pharmaceutical Organization (GPO), Thailand) 0.5 mg/kg will be given once daily with food for 14 days. This is the dose recommended for radical cure of P. vivax in tropical areas with high rates of relapse, such as the study design setting. Doses will be directly supervised (DOT).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafenoquine
Description: Tafenoquine (Kodatef, Biocelect Pty Ltd.) 300 mg will be given as a directly observed single dose with food. This is the standard dose recommended globally for radical cure of P. vivax.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafenoquine
Description: Tafenoquine (Kodatef, Biocelect Pty Ltd.) 300 mg will be given as a directly observed single dose with food. This is the standard dose recommended globally for radical cure of P. vivax.